A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy
Version of Record online: 15 MAY 2007
2007, IGCS and ESGO
International Journal of Gynecological Cancer
Volume 18, Issue 1, pages 51–58, January/February 2008
How to Cite
COMANDER, A.H. and CANNISTRA, S.A. (2008), A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy. International Journal of Gynecological Cancer, 18: 51–58. doi: 10.1111/j.1525-1438.2007.00978.x
- Issue online: 14 DEC 2007
- Version of Record online: 15 MAY 2007
- Accepted for publication March 1, 2007
- 3Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183–93., , et al.
- 7Paclitaxel/carboplatin vs. paclitaxel/carboplatin followed by topotecan in first-line treatment of advanced ovarian cancer. Mature results of a gynecologic cancer intergroup phase III trial of the AGO OVAR and GINECO [abstract]. ASCO 2005;23:456 Abstracts 2005., , et al.
- 17Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460–5., , et al.
- 18Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I 2006;24(Suppl.):2575., , , , , .